Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

Darwin W Kwok,Nicholas O Stevers,Takahide Nejo,Lee H Chen,Inaki Etxeberria,Jangham Jung,Kaori Okada,Maggie Colton Cove,Senthilnath Lakshmanachetty,Marco Gallus,Abhilash Barpanda,Chibo Hong,Gary K L Chan,Samuel H Wu,Emilio Ramos,Akane Yamamichi,Jerry Liu,Payal Watchmaker,Hirokazu Ogino,Atsuro Saijo,Aidan Du,Nadia Grishanina,James Woo,Aaron Diaz,Susan M Chang,Joanna J Phillips,Arun P Wiita,Christopher A Klebanoff,Joseph F Costello,Hideho Okada

DOI: https://doi.org/10.1101/2023.10.19.563178

2023-10-20

bioRxiv

Abstract:T-cell-mediated immunotherapies are limited by the extent to which cancer-specific antigens are homogenously expressed throughout a tumor. We reasoned that recurrent splicing aberrations in cancer represent a potential source of tumor-wide and public neoantigens, and to test this possibility, we developed a novel pipeline for identifying neojunctions expressed uniformly within a tumor across diverse cancer types. Our analyses revealed multiple neojunctions that recur across patients and either exhibited intratumor heterogeneity or, in some cases, were tumor-wide. We identified CD8+ T-cell clones specific for neoantigens derived from tumor-wide and conserved neojunctions in GNAS and RPL22 , respectively. TCR-engineered CD8 + T-cells targeting these mutations conferred neoantigen-specific tumor cell eradication. Furthermore, we revealed that cancer-specific dysregulation in splicing factor expression leads to recurrent neojunction expression. Together, these data reveal that a subset of neojunctions are both intratumorally conserved and public, providing the molecular basis for novel T-cell-based immunotherapies that address intratumoral heterogeneity.